Working… Menu

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00243568
Recruitment Status : Withdrawn
First Posted : October 24, 2005
Last Update Posted : September 12, 2019
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Primary Completion Date : No date given
Study Completion Date : No date given